Virus-modified homologus tumor-cell extract in the treatment of vulvar carcinoma

R. S. Freedman, J. M. Bowen, J. Herson, J. T. Wharton, F. N. Rutledge, A. D. Hamberger

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Eight patients with squamous carcinoma of the vulva and two or more positive nodes have received adjunctive immunotherapy with a virus modified homologous cell extract. Seven of eight patients received radiation therapy in addition. Cells derived from the SW962 vulvar carcinoma cell line were infected with PR8/A/34 strain of influenza and a membrane extract was used for immunization. The extract was administered by the intradermal route weekly for three doses and then biweekly for up to 2 years. Each dose is equivalent to 1.5 mg protein. None of the patients have recurred and durations of remission are 24, 24, 22, 22, 21, 16, 7, and 2 months respectively. This compares favourably with similar groups of patients who were treated with surgery alone (22/33 recurred, median recurrence time 14.8 months) or surgery plus radiation therapy (8/9 recurrences, median recurrence time 11.0 months). No serious side effects have occurred with more than 200 doses of extract. Post immunization monitoring has indicated good in vitro and in vivo immunological responses and antibody titers to PR8 increased significantly in five of eight patients.

Original languageEnglish (US)
Pages (from-to)33-38
Number of pages6
JournalCancer Immunology Immunotherapy
Issue number1
StatePublished - Apr 1980
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Virus-modified homologus tumor-cell extract in the treatment of vulvar carcinoma'. Together they form a unique fingerprint.

Cite this